Antipsychotics for cocaine or psychostimulant dependence: Systematic review and meta-analysis of randomized, placebo-controlled trials

Journal of Clinical Psychiatry

Volumn 74, Issue 12, 2013, Pages

  Kishi, Taro ^a,b   Matsuda, Yuki ^a   Iwata, Nakao ^a   Correll, Christoph U ^b,c,d,e,f  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Division of Psychiatry Research Zucker Hillside Hospital North Shore Long Island Jewish Health System ^*  (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; ARIPIPRAZOLE; COCAINE; METHAMPHETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOSTIMULANT AGENT; RESERPINE; RISPERIDONE;

AMPHETAMINE DEPENDENCE; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COCAINE DEPENDENCE; COCHRANE LIBRARY; DATA EXTRACTION; DEPRESSION; DISEASE ACTIVITY; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; METHAMPHETAMINE DEPENDENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSTIMULANT DRUG DEPENDENCE; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFORCEMENT; SUBSTANCE USE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

AMPHETAMINE-RELATED DISORDERS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; HUMANS; METHAMPHETAMINE; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SUBSTANCE WITHDRAWAL SYNDROME; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 84891388651     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13r08525     Document Type: Article

References (75)

1. DiGregorio GJ. Cocaine update: abuse and therapy. Am Fam Physician. 1990;41(1):247-250.
2. Rawson RA. Treatment for Stimulant Use Disorders. Rockville, MD: US Department of Health and Human Services; 2011.
3. Dackis CA, O?Brien CP. Cocaine dependence: a disease of the brain?s reward centers. J Subst Abuse Treat. 2001;21(3):111-117.
4. Gawin FH, Ellinwood EH Jr. Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med. 1988;318(18):1173-1182.
5. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry. 1986;43(2):107-113.
6. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin. 2011;29(3):641-655.
7. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry. 1999;4(6):512-523.
8. D?Souza MS, Markou A. Neural substrates of psychostimulant withdrawalinduced anhedonia. Curr Top Behav Neurosci. 2010;3:119-178.
9. Buttner A. Review: the neuropathology of drug abuse. Neuropathol Appl Neurobiol. 2011;37(2):118-134.
10. Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406-433.
11. Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011;69(4):650-663.
12. Patkar AA, Murray HW, Mannelli P, et al. Pre-treatment measures of impulsivity, aggression and sensation seeking are associated with treatment outcome for African-American cocaine-dependent patients. J Addict Dis. 2004;23(2):109-122.
13. Amato L, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2007;(3):CD006306.
14. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26(1):9-12.
15. Berger SP, Hall S, Mickalian JD, et al. Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 1996;347(9000):504-508.
16. Moher D, Liberati A, Tetzlaff J, et al, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
17. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116-141.
18. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? a systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(4):486-496.
19. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
20. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071.
21. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70(3): 265-273.
22. Berger SP, Winhusen TM, Somoza EC, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction. 2005;100(suppl 1):58-67.
23. Levin FR, McDowell D, Evans SM, et al. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am J Addict. 1999;8(2):120-127.
24. Loebl T, Angarita GA, Pachas GN, et al. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry. 2008;69(3):480-486.
25. Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction. 2005;100(suppl 1):43-57.
26. Hamilton JD, Nguyen QX, Gerber RM, et al. Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. Am J Addict. 2009; 18(1):48-52.
27. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol. 2000;20(3):305-310.
28. Coffin PO, Santos GM, Das M, et al. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebocontrolled trial. Addiction. 2013;108(4):751-761.
29. Sulaiman AH, Gill JS, Said MA, et al. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract. 2013;17(2):131-138.
30. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis. 1980;168(1):26-33.
31. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90(5):607-614.
32. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
33. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery. 2nd ed. Chevy Chase, MD: National Institute of Mental Health; 1970.
34. Winhusen T, Somoza E, Sarid-Segal O, et al. A double-blind, placebocontrolled trial of reserpine for the treatment of cocaine dependence. Drug Alcohol Depend. 2007;91(2-3):205-212.
35. Somoza E, Dyrenforth S, Goldsmith J, et al. ?In search of a universal drug craving scale.? Paper presented at the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Florida.
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
37. Newton TF, Reid MS, De La Garza R, et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2008;11(8):1037-1045.
38. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571.
39. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
40. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-tohead comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
42. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003;327(7414):557-560.
43. Johnson BA, Ait-Daoud N, Elkashef AM, et al; Methamphetamine Study Group. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008;11(1):1-14.
44. Johnson BA, Roache JD, Ait-Daoud N, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend. 2006;84(3):256-263.
45. Johnson BA, Chen YR, Swann AC, et al. Ritanserin in the treatment of cocaine dependence. Biol Psychiatry. 1997;42(10):932-940.
46. Cornish JW, Maany I, Fudala PJ, et al. A randomized, double-blind, placebocontrolled study of ritanserin pharmacotherapy for cocaine dependence. Drug Alcohol Depend. 2001;61(2):183-189.
47. Nejtek VA, Avila M, Chen LA, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized double-blind trial. J Clin Psychiatry. 2008;69(8):1257-1266.
48. Ersche KD, Bullmore ET, Craig KJ, et al. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry. 2010;67(6):632-644.
49. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004;29(5):969-981.
50. Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27(1): 45-49.
51. Tiihonen J, Kuoppasalmi K, Fohr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007;164(1):160-162.
52. Brunetti M, Di Tizio L, Dezi S, et al. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci. 2012;16(10):1346-1354.
53. Alvarez Y, Perez-Mana C, Torrens M, et al. Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat.2013;45(1):1-10.
54. Zhornitsky S, Rizkallah E, Pampoulova T, et al. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol. 2010;30(4):417-424.
55. Somaini L, Donnini C, Raggi MA, et al. Promising medications for cocaine dependence treatment. Recent Pat CNS Drug Discov. 2011;6(2):146-160.
56. Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry. 2011;16(10):974-986.
57. Meini M, Moncini M, Cecconi D, et al. Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study. Curr Pharm Des.2011;17(14):1376-1383.
58. Machielsen M, Beduin AS, Dekker N, et al; Genetic Risk and Outcome of Psychosis (GROUP) investigators. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2012;26(1):189-195.
59. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substanceabusing individuals with schizophrenia. Am J Addict. 2007;16(4):260-268.
60. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104.
61. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21.
62. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;(12):CD008121.
63. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657):31-41.
64. De Los Cobos JP, Sinol N, Trujols J, et al. Drug-dependent inpatients reporting continuous absence of spontaneous drug craving for the main substance throughout detoxification treatment. Drug Alcohol Rev. 2011; 30(4):403-410.
65. Kishi T, Fukuo Y, Okochi T, et al. Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. Drug Alcohol Depend. 2011;113(1):1-7.
66. Brown JC, Rizvi S, Klein EJ, et al. Hydroscopic properties of organic objects that may present as aural foreign bodies. J Clin Med Res. 2010; 2(4):172-176.
67. Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23(4): 384-388.
68. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
69. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs: nature reviews. Endocrinology. 2012;8(2):114-126.
70. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107.
71. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167-177.
72. Mandyam CD, Koob GF. The addicted brain craves new neurons: putative role for adult-born progenitors in promoting recovery. Trends Neurosci.2012;35(4): 250-260.
73. Koob GF, Zorrilla EP. Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor. Curr Opin Investig Drugs. 2010;11(1):63-71.
74. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217-238.
75. Schuckit MA, Tipp JE, Bucholz KK, et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction. 1997;92(10):1289-1304.